216 related articles for article (PubMed ID: 34607367)
1. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
2. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
3. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
4. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients.
Yavuz DG; Yazan CD; Hekimsoy Z; Aydin K; Gokkaya N; Ersoy C; Akalın A; Topaloglu O; Aydogan BI; Dilekci ENA; Alphan Uc Z; Cansu GB; Ozsari L; Iyidir OT; Olgun ME; Keskin L; Mert M; Can B; Gungor K; Galip T; Cantürk Z; Elbuken G; Pekkolay Z; Kutbay NO; Yorulmaz G; Kalkan AT; Unsal YA; Yay A; Karagun B; Bozkur E
Clin Endocrinol (Oxf); 2022 Dec; 97(6):833-840. PubMed ID: 35639050
[TBL] [Abstract][Full Text] [Related]
5. Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Kudo T; Nishihara E; Kihara M; Ito Y; Miya A; Fukata S; Nishikawa M; Nakamura H
Endocr J; 2019 Nov; 66(11):953-960. PubMed ID: 31270299
[TBL] [Abstract][Full Text] [Related]
6. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
[No Abstract] [Full Text] [Related]
7. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma.
Gülsoy Kirnap N; Turhan Iyidir Ö; Bozkuş Y; Işildak ŞM; Anil C; Firat SN; Demir C; Nar A; Başçil Tütüncü N
Turk J Med Sci; 2020 Jun; 50(4):870-876. PubMed ID: 32490648
[TBL] [Abstract][Full Text] [Related]
8. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
[TBL] [Abstract][Full Text] [Related]
9. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
10. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
11. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
12. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
13. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
14. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
15. Effects of Levothyroxine Replacement or Suppressive Therapy on Energy Expenditure and Body Composition.
Samuels MH; Kolobova I; Smeraglio A; Peters D; Purnell JQ; Schuff KG
Thyroid; 2016 Mar; 26(3):347-55. PubMed ID: 26700485
[TBL] [Abstract][Full Text] [Related]
16. Identification of Resistance to Exogenous Thyroxine in Humans.
Lacámara N; Lecumberri B; Barquiel B; Escribano A; González-Casado I; Álvarez-Escolá C; Aleixandre-Blanquer F; Morales F; Alfayate R; Bernal-Soriano MC; Miralles R; Yildirim Simsir I; Özgen AG; Bernal J; Berbel P; Moreno JC
Thyroid; 2020 Dec; 30(12):1732-1744. PubMed ID: 32498666
[No Abstract] [Full Text] [Related]
17. Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy.
Brun VH; Eriksen AH; Selseth R; Johansson K; Vik R; Davidsen B; Kaut M; Hellemo L
Thyroid; 2021 Sep; 31(9):1297-1304. PubMed ID: 33980057
[No Abstract] [Full Text] [Related]
18. Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.
Freudenthal B; Williams GR
Clin Oncol (R Coll Radiol); 2017 May; 29(5):325-328. PubMed ID: 28043744
[TBL] [Abstract][Full Text] [Related]
19. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
[TBL] [Abstract][Full Text] [Related]
20. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
